These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 1706731)

  • 1. Prospective study of the association between serum antibodies to lipopolysaccharide O antigen and the attack rate of shigellosis.
    Cohen D; Green MS; Block C; Slepon R; Ofek I
    J Clin Microbiol; 1991 Feb; 29(2):386-9. PubMed ID: 1706731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum antibodies to lipopolysaccharide and natural immunity to shigellosis in an Israeli military population.
    Cohen D; Green MS; Block C; Rouach T; Ofek I
    J Infect Dis; 1988 May; 157(5):1068-71. PubMed ID: 3283258
    [No Abstract]   [Full Text] [Related]  

  • 3. Detection of antibodies to Shigella lipopolysaccharide in urine after natural Shigella infection or vaccination.
    Cohen D; Orr N; Robin G; Slepon R; Ashkenazi S; Ashkenazi I; Shemer J
    Clin Diagn Lab Immunol; 1996 Jul; 3(4):451-5. PubMed ID: 8807212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development, Interlaboratory Evaluations, and Application of a Simple, High-Throughput
    Nahm MH; Yu J; Weerts HP; Wenzel H; Tamilselvi CS; Chandrasekaran L; Pasetti MF; Mani S; Kaminski RW
    mSphere; 2018 Jun; 3(3):. PubMed ID: 29898979
    [No Abstract]   [Full Text] [Related]  

  • 5. Sociodemographic factors associated with serum anti-Shigella lipopolysaccharide antibodies and shigellosis.
    Cohen D; Slepon R; Green MS
    Int J Epidemiol; 1991 Jun; 20(2):546-50. PubMed ID: 1917263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults.
    Cohen D; Ashkenazi S; Green MS; Gdalevich M; Robin G; Slepon R; Yavzori M; Orr N; Block C; Ashkenazi I; Shemer J; Taylor DN; Hale TL; Sadoff JC; Pavliakova D; Schneerson R; Robbins JB
    Lancet; 1997 Jan; 349(9046):155-9. PubMed ID: 9111538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural immunity to shigellosis in two groups with different previous risks of exposure to Shigella is only partly expressed by serum antibodies to lipopolysaccharide.
    Cohen D; Green MS; Block C; Slepon R; Lerman Y
    J Infect Dis; 1992 Apr; 165(4):785-7. PubMed ID: 1552217
    [No Abstract]   [Full Text] [Related]  

  • 8. Quantitative analysis of IgG class and subclass and IgA serum response to Shigella sonnei and Shigella flexneri 2a polysaccharides following vaccination with Shigella conjugate vaccines.
    Robin G; Keisari Y; Slepon R; Ashkenazi S; Cohen D
    Vaccine; 1999 Aug; 17(23-24):3109-15. PubMed ID: 10462247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune Response Characterization after Controlled Infection with Lyophilized Shigella sonnei 53G.
    Clarkson KA; Frenck RW; Dickey M; Suvarnapunya AE; Chandrasekaran L; Weerts HP; Heaney CD; McNeal M; Detizio K; Parker S; Hoeper A; Bourgeois AL; Porter CK; Venkatesan MM; Kaminski RW
    mSphere; 2020 Sep; 5(5):. PubMed ID: 32968012
    [No Abstract]   [Full Text] [Related]  

  • 10. Shigellosis in Vietnam: seroepidemiologic studies with use of lipopolysaccharide antigens in enzyme immunoassays.
    Lindberg AA; Cam PD; Chan N; Phu LK; Trach DD; Lindberg G; Karlsson K; Kärnell A; Ekwall E
    Rev Infect Dis; 1991; 13 Suppl 4():S231-7. PubMed ID: 2047643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum IgG antibodies to
    Cohen D; Meron-Sudai S; Bialik A; Asato V; Goren S; Ariel-Cohen O; Reizis A; Hochberg A; Ashkenazi S
    Hum Vaccin Immunother; 2019; 15(6):1401-1408. PubMed ID: 31070988
    [No Abstract]   [Full Text] [Related]  

  • 12. Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children.
    Passwell JH; Ashkenazi S; Harlev E; Miron D; Ramon R; Farzam N; Lerner-Geva L; Levi Y; Chu C; Shiloach J; Robbins JB; Schneerson R;
    Pediatr Infect Dis J; 2003 Aug; 22(8):701-6. PubMed ID: 12913770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Shigella lipopolysaccharide antibodies in pediatric populations.
    Passwell JH; Freier S; Shor R; Farzam N; Block C; Lison M; Shiff E; Ashkenazi S
    Pediatr Infect Dis J; 1995 Oct; 14(10):859-65. PubMed ID: 8584312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Threshold protective levels of serum IgG to Shigella lipopolysaccharide: re-analysis of Shigella vaccine trials data.
    Cohen D; Ashkenazi S; Schneerson R; Farzam N; Bialik A; Meron-Sudai S; Asato V; Goren S; Baran TZ; Muhsen K; Gilbert PB; MacLennan CA
    Clin Microbiol Infect; 2023 Mar; 29(3):366-371. PubMed ID: 36243351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of Shigella sonnei and Shigella flexneri 2a O-specific polysaccharide conjugates in children.
    Ashkenazi S; Passwell JH; Harlev E; Miron D; Dagan R; Farzan N; Ramon R; Majadly F; Bryla DA; Karpas AB; Robbins JB; Schneerson R
    J Infect Dis; 1999 Jun; 179(6):1565-8. PubMed ID: 10228084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel.
    Passwell JH; Harlev E; Ashkenazi S; Chu C; Miron D; Ramon R; Farzan N; Shiloach J; Bryla DA; Majadly F; Roberson R; Robbins JB; Schneerson R
    Infect Immun; 2001 Mar; 69(3):1351-7. PubMed ID: 11179298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective cohort studies of shigellosis during military field training.
    Cohen D; Sela T; Slepon R; Yavzori M; Ambar R; Orr N; Robin G; Shpielberg O; Eldad A; Green M
    Eur J Clin Microbiol Infect Dis; 2001 Feb; 20(2):123-6. PubMed ID: 11305466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization and quantitative analysis of serum IgG class and subclass response to Shigella sonnei and Shigella flexneri 2a lipopolysaccharide following natural Shigella infection.
    Robin G; Cohen D; Orr N; Markus I; Slepon R; Ashkenazi S; Keisari Y
    J Infect Dis; 1997 May; 175(5):1128-33. PubMed ID: 9129076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination with Shigella flexneri 2a conjugate induces type 2a and cross-reactive type 6 antibodies in humans but not in mice.
    Farzam N; Ramon-Saraf R; Banet-Levi Y; Lerner-Geva L; Ashkenazi S; Kubler-Kielb J; Vinogradov E; Robbins JB; Schneerson R
    Vaccine; 2017 Sep; 35(37):4990-4996. PubMed ID: 28797729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunoglobulin M, A, and G antibody response to lipopolysaccharide O antigen in symptomatic and asymptomatic Shigella infections.
    Cohen D; Block C; Green MS; Lowell G; Ofek I
    J Clin Microbiol; 1989 Jan; 27(1):162-7. PubMed ID: 2463995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.